Does TAVI improve clinical outcomes in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis?
TAVI is feasible and provides symptomatic and functional benefits in survivors with low-flow, low-gradient aortic stenosis and severe comorbidities, despite high early mortality.
Our study suggests that TAVI is feasible in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis. Within the first 6 months after treatment all-cause mortality was considerable high, but the surviving patients showed symptomatic benefit and significant improvement of myocardial function and exercise capacity.
Gotzmann et al. (Fri,) studied this question.